Emerging Biopharma

Latest News

February 14th 2025

Q&A: Gain Therapeutics CEO Discusses AI-Driven Drug Discovery, Strategic Growth Plans

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial intelligence in the drug discovery process.

February 13th 2025

Latent Labs Launches Publicly with $50 Million in Funding for Artificial Intelligence-Powered Programmable Biology

By Don Tracy, Associate Editor

February 12th 2025

Abcuro Secures $200 Million in Series C Funding to Advance Ulviprubart for Inclusion Body Myositis

By Don Tracy, Associate Editor

January 30th 2025

ImmunityBio, BeiGene Strike Deal to Conduct Phase III Trial for Tislelizumab, Anktiva in Advanced or Metastatic Non-Small Cell Lung Cancer

By Don Tracy, Associate Editor

January 27th 2025

Exploring Biopharma's Dealmaking Terrain, Roadmap in China

By Adam Zhang Yu

Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health

ByDon Tracy, Associate Editor

January 22nd 2025

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

Teva Agrees to Strategic Partnerships with Formycon AG, Klinge Biopharma, & Samsung Bioepis

ByDon Tracy, Associate Editor

January 14th 2025

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

Emerging Biopharma

Latest News

Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health

Teva Agrees to Strategic Partnerships with Formycon AG, Klinge Biopharma, & Samsung Bioepis

Trending on PharmExec

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program

FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease

Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy